← Leaderboards
Jerry L Blackwell
University Of Alabama At Birmingham
$3,403,008
Attributed
$3,403,008
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $772.9K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,403,008 · 15
By mechanism
R01$1,467,995 · 1
R21$1,249,919 · 3
P51$685,094 · 11
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Eric Hunter$78,178,241
- Jamil Subhi Saad$6,938,316
- Beatrice H Hahn$74,097,732
- William J Britt$28,989,956
- Richard W Compans$30,337,837
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensVaccinesBaseHiv-1InfectionDendritic CellsResearch PersonnelAdenovirusesVariantResourcesVectorGrantUnited States National Institutes Of HealthFundingSourceAdenovirus VectorVaccine CandidateDesignNeutralizing AntibodyTransmission ProcessGenesGeneticImmunizationVector Vaccine
Grant awards (21)
Escape From Broadly Neutralizing MAbs by Genetically-Linked Early & Late HIV Envs$264,000
R21 · FY2012 · AI · contact PI
NOVEL ADENOVIRUS-VECTORED HIV VACCINE THAT KNOCKS THE SOCS1 OFF DENDRITIC CELLS$74,294
P51 · FY2011 · RR · contact PI
HIV-1 VACCINE CANDIDATES USING NEWLY TRANSMITTED CLADE C ENVS AS IMMUNOGENS$74,294
P51 · FY2011 · RR · contact PI
Novel HIV-1 vaccine candidates using newly transmitted clade C Envs as immunogens$369,295
R01 · FY2010 · AI · contact PI
NOVEL ADENOVIRUS-VECTORED HIV VACCINE THAT KNOCKS THE SOCS1 OFF DENDRITIC CELLS$54,827
P51 · FY2010 · RR · contact PI
HIV-1 VACCINE CANDIDATES USING NEWLY TRANSMITTED CLADE C ENVS AS IMMUNOGENS$54,827
P51 · FY2010 · RR · contact PI
Novel HIV-1 vaccine candidates using newly transmitted clade C Envs as immunogens$373,025
R01 · FY2009 · AI · contact PI
Development and evaluation of a novel SOCS1-silenced HIV vaccine$220,000
R21 · FY2009 · AI · contact PI
HIV-1 VACCINE CANDIDATES USING NEWLY TRANSMITTED CLADE C ENVS AS IMMUNOGENS$56,690
P51 · FY2009 · RR · contact PI
NOVEL ADENOVIRUS-VECTORED HIV VACCINE THAT KNOCKS THE SOCS1 OFF DENDRITIC CELLS$56,690
P51 · FY2009 · RR · contact PI
Novel HIV-1 vaccine candidates using newly transmitted clade C Envs as immunogens$373,025
R01 · FY2008 · AI · contact PI
Development and evaluation of a novel SOCS1-silenced HIV vaccine$264,000
R21 · FY2008 · AI · contact PI
NOVEL ADENOVIRUS-VECTORED HIV VACCINE THAT KNOCKS THE SOCS1 OFF DENDRITIC CELLS$67,958
P51 · FY2008 · RR · contact PI
HIV-1 VACCINE CANDIDATES USING NEWLY TRANSMITTED CLADE C ENVS AS IMMUNOGENS$67,958
P51 · FY2008 · RR · contact PI
Novel HIV-1 vaccine candidates using newly transmitted clade C Envs as immunogens$352,650
R01 · FY2007 · AI · contact PI
IN SITU GENE-MODIFIED DCS FOR AN HIV-1 T CELL VACCINE$65,453
P51 · FY2007 · RR · contact PI
IN SITU GENE-MODIFIED DCS FOR AN HIV-1 T CELL VACCINE$59,665
P51 · FY2006 · RR · contact PI
IN SITU GENE-MODIFIED DCS FOR AN HIV-1 T CELL VACCINE$52,438
P51 · FY2005 · RR
In situ gene-modified DCs for an HIV-1 T cell vaccine$198,357
R21 · FY2004 · AI
In situ gene-modified DCs for an HIV-1 T cell vaccine$61,062
R21 · FY2004 · AI
In situ gene-modified DCs for an HIV-1 T cell vaccine$242,500
R21 · FY2003 · AI